Literature DB >> 233249

Lymphocyte purine metabolism -- significance of 5'-nucleotidase deficiency: a review.

A D Webster, N Matamoros.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 233249      PMCID: PMC1437037          DOI: 10.1177/014107687907200407

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  16 in total

Review 1.  Membrane transport of purine and pyrimidine bases and nucleosides in animal cells.

Authors:  R D Berlin; J M Oliver
Journal:  Int Rev Cytol       Date:  1975

2.  Identification of hypoxanthine as the major compoenet of a chromatographic fraction of transfer factor.

Authors:  M S O'Dorisio; J A Neidhart; F B Daniel; S P Balcerzak; A F LoBuglio
Journal:  Cell Immunol       Date:  1976-05       Impact factor: 4.868

3.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

4.  Studies on the lymphocyte 5'-nucleotidase in chronic lymphocytic leukemia, infectious mononucleosis, normal subpopulations, and phytohemagglutinin-stimulated cells.

Authors:  F Quagliata; D Faig; M Conklyn; R Silber
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

5.  Lymphocyte purine 5'-nucleotidase edficiency in primary hypogammaglobulinaemia.

Authors:  S M Johnson; M E North; G L Asherson; J Allsop; R W Watts; A D Webster
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

6.  Surface localization of 5'-nucleotidase on the mouse lymphocyte.

Authors:  R J Uusitalo; M J Karnovsky
Journal:  J Histochem Cytochem       Date:  1977-02       Impact factor: 2.479

7.  Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation.

Authors:  A C Allison; T Hovi; R W Watts; A D Webster
Journal:  Lancet       Date:  1975-12-13       Impact factor: 79.321

8.  Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency.

Authors:  S H Polmar; R C Stern; A L Schwartz; E M Wetzler; P A Chase; R Hirschhorn
Journal:  N Engl J Med       Date:  1976-12-09       Impact factor: 91.245

9.  Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency.

Authors:  J W Stoop; B J Zegers; G F Hendrickx; L H van Heukelom; G E Staal; P K de Bree; S K Wadman; R E Ballieux
Journal:  N Engl J Med       Date:  1977-03-24       Impact factor: 91.245

10.  Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity.

Authors:  E R Giblett; A J Ammann; D W Wara; R Sandman; L K Diamond
Journal:  Lancet       Date:  1975-05-03       Impact factor: 79.321

View more
  2 in total

1.  Studies on the kinetic properties and subcellular localization of adenine nucleotide phosphatases in peripheral blood lymphocytes from control subjects and patients with common variable primary hypogammaglobulinaemia.

Authors:  G P Smith; T Shah; A D Webster; T J Peters
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

2.  Levels of adenosine deaminase in some experimental animal tumours and the possible therapeutic effect of the ADA inhibitor 2-deoxy-coformycin.

Authors:  J G Hall; L Gyure; J Peppard; E Orlans
Journal:  Br J Cancer       Date:  1979-11       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.